Moleculin Biotech reports European patent progress in latest 8-K

Rhea-AI Filing Summary

Item 7.01 – Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application “Preparation of Pre-liposomal Annamycin Lyophilizate.”

The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company’s Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.

Positive

• Received Notice of Intent to Grant for European patent covering Pre-liposomal Annamycin Lyophilizate, enhancing prospective IP protection in a key market.

Negative

• None.

Insights

Equity Research Analyst

TL;DR: European patent notice modestly improves MBRX competitive moat; financial impact not yet quantifiable.

The notice of intent to grant extends future intellectual-property protection for Annamycin, Moleculin’s lead oncology candidate. Stronger IP in a major market can enhance pricing power and partnering leverage, supporting long-term value. However, with no accompanying clinical or revenue data, the immediate valuation effect is limited. Given Moleculin’s development-stage status, any IP progress is material but preliminary.

Biotech IP Specialist

TL;DR: Pending EU patent reduces regulatory risk for Annamycin formulation, a clear strategic positive.

An EU “notice of intent” typically precedes formal patent issuance within months, locking in 20-year protection from the filing date. This strengthens Moleculin’s bargaining position for regional licensing or funding. The filing lacks details on claims scope, but simply advancing to grant stage is a de-risking milestone for a small-cap biotech.

false 0001659617 0001659617 2025-07-30 2025-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 30, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On July 30, 2025, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that the Company has received a Notice of Intent to Grant for the European patent application titled, “Preparation of Preliposomal Annamycin Lyophilizate.”

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Releasedated July 30, 2025

104 Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	July 30, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster

FAQ

What did Moleculin Biotech (MBRX) disclose in its 30 July 2025 Form 8-K?

It announced a Notice of Intent to Grant for its European patent application titled “Preparation of Pre-liposomal Annamycin Lyophilizate.”

Which item of Form 8-K does the disclosure fall under?

Item 7.01 – Regulation FD Disclosure.

Does the filing include financial statements or earnings data?

No. The 8-K only furnishes the patent notice press release; no financial data is provided.

Where can investors read the full press release?

The press release is attached as Exhibit 99.1 to the 8-K.

Is the disclosed information considered filed or furnished?

It is furnished, not filed, meaning it will not be incorporated into other SEC filings unless specifically referenced.